Andrea Gissi

Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization

Katie Paul Friedman, Matthew Gagné, Lit‐Hsin Loo et al. · Toxicological Sciences · 2019 · 245 citations · Full text

Pharmacy, Toxicology, Environmental Toxicology +16

Evaluation and comparison of benchmark QSAR models to predict a relevant REACH endpoint: The bioconcentration factor (BCF)

Andrea Gissi, Anna Lombardo, Alessandra Roncaglioni et al. · Environmental Research · 2015 · 58 citations

Pharmacy, Pharmacology, Dose-response Modeling +13

An alternative QSAR-based approach for predicting the bioconcentration factor for regulatory purposes

Andrea Gissi, Domenico Gadaleta, Matteo Floris et al. · ALTEX · 2014 · 52 citations · Full text

Pharmacy, Toxicology, Drug Discovery +12

Automated and standardized workflows in the OECD QSAR Toolbox

Darina Yordanova, T.W. Schultz, Chanita Kuseva et al. · Computational Toxicology · 2019 · 49 citations

Pharmacy, Medicinal Chemistry, Drug Design +8

The OECD (Q)SAR Assessment Framework: A tool for increasing regulatory uptake of computational approaches

Andrea Gissi, Olga Tcheremenskaia, Cecilia Bossa et al. · Computational Toxicology · 2024 · 39 citations · Full text

Pharmacy, Toxicology, Regulatory Science +7